NCT00508989View on ClinicalTrials.gov

Niacin to Improve Blood Flow in People With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 24, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 24, 2015

Conditions
Sickle Cell Disease
Interventions
DRUG

Niacin-ER

500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks

DRUG

Placebo

500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks

DRUG

L-NMMA

DRUG

Acetylcholine

Trial Locations (2)

20060

Howard University Hospital, Washington D.C.

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00508989 - Niacin to Improve Blood Flow in People With Sickle Cell Disease | Biotech Hunter | Biotech Hunter